B+
Bull case
20%
Probability
Target price
$3.25
+47.1% vs current
YDES
Breeze AcquisitionCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$2.20
-0.5% vs current
B-
Bear case
30%
Probability
Target price
$1.50
-32.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-21
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+46.2
Score
AI commentary
Recent-news, social, options, short-interest, and employee-sentiment coverage is unavailable in the packet. The July 20 price decline is observable but unattributed; missing analyst reaction is not positive evidence. Confidence is therefore capped and the memo remains monitoring-oriented.
RankAlpha Sentiment Codex - 2026-07-21
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-24catalystFragile near-term trading momentumHigh impact
YDES closed at $2.27 on July 20 after opening at $2.45, a 7.35% decline; no trusted source links the move to earnings, so near-term sentiment remains fragile.
2026-10-19eventEarnings follow-up remains unconfirmedMedium impact
The packet schedules a July 20 earnings follow-up, but no July 20 company release, 8-K, or transcript was available. Treat the event as unresolved rather than as a confirmed beat or miss.
2027-07-21catalystPotential 2026 regulatory and clinical milestonesHigh impact
Management reported completed CMC work and FDA DMF filings for its LSC and exosome platforms, with planned 2026 IND submissions for dry eye disease and AMD plus an OkaiDx FDA Q-Submission. These are plans, not approvals or clinical readouts. [#PR-EARNINGS-2026-05-01]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology